The latest update is out from Simcere Pharmaceutical Group Limited ( (HK:2096) ).
Simcere Pharmaceutical Group Limited announced a supplemental update regarding the renewal of its continuing connected transactions under the Diagnostics R&D Project Service Framework Agreement and the BioSciKin Property Lease and Comprehensive Services Framework Agreement. The company highlighted changes in its pricing policy and provided an outlook on the anticipated demand for R&D services, driven by the need for biomarker and multi-omics detection, discovery, and analysis services to enhance the value of its clinical studies and expand its product indications.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited, incorporated in Hong Kong, operates within the pharmaceutical industry. The company, along with its subsidiaries, focuses on research and development, production, and marketing of pharmaceutical products, with a particular emphasis on diagnostics and R&D project services.
YTD Price Performance: -7.61%
Average Trading Volume: 5,517,162
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: HK$16.63B
See more insights into 2096 stock on TipRanks’ Stock Analysis page.